development agreement with Adalvo for semaglutide injection -statement

Gedeon Richter

06/05/2025 07:07

May 6 (Reuters) - Richter Gedeon Vegyeszeti Gyar Nyrt GDRB.BU says:

IT ENTERS A GLOBAL CO-DEVELOPMENT AGREEMENT WITH ADALVO FOR SEMAGLUTIDE INJECTION -STATEMENT

AGREEMENT IS FOR PROPOSED BIOEQUIVALENT TO SEMAGLUTIDE INJECTION, A GLP-1 RECEPTOR AGONIST INDICATED FOR CHRONIC WEIGHT MANAGEMENT

THE AGREEMENT COVERS GLOBAL RIGHTS, WITH BOTH COMPANIES SHARING DEVELOPMENT COSTS AND NET PROFITS ACROSS EACH OTHER'S MARKETS

Source text: [https://bet.hu/newkibdata/129251875/Semaglutide_6May2025_ENG.pdf]

Further company coverage: GDRB.BU

 (Reporting by Anita Komuves)

 ((KOMUVES.Anita@thomsonreuters.com;))